Emcure Pharmaceuticals (EMCURE) Q4 23/24 earnings summary

Executive summary

• Consolidated revenue from operations grew to Rs. 66,582.5 million for FY 2023-24, up from Rs. 59,858.1 million year-over-year.

• Consolidated profit for the year was Rs. 5,275.8 million, compared to Rs. 5,618.4 million in the previous year.

• Standalone revenue from operations reached Rs. 34,976.6 million, with standalone profit for the year at Rs. 1,608.3 million.

• The group completed the acquisition of Mantra Pharma Inc. in Canada, expanding its international footprint.

Financial highlights

• Consolidated EBITDA was Rs. 12,867.1 million, up from Rs. 12,270.9 million year-over-year.

• Consolidated EPS stood at Rs. 27.54, down from Rs. 29.42 in the previous year.

• Standalone EPS was Rs. 8.89, marginally up from Rs. 8.85 year-over-year.

• Consolidated gross margin improved, with cost of materials consumed at Rs. 13,331.3 million (consolidated) and Rs. 10,878.2 million (standalone).

• Dividend payout for the year totaled Rs. 542.6 million, including interim and final dividends.

Outlook and guidance

• The company continues to focus on expanding its product portfolio and international presence, with ongoing investments in R&D and manufacturing capacity.

• Management expects continued growth in both domestic and international markets, supported by new launches and strategic partnerships.